Total Payments
$111,551
2024 Payments
$16,269
Companies
17
Transactions
93
Medicare Patients
508
Medicare Billing
$66,347
Payment Breakdown by Category
Consulting$58,486 (52.4%)
Research$36,527 (32.7%)
Other$12,030 (10.8%)
Food & Beverage$2,782 (2.5%)
Travel$1,577 (1.4%)
Education$148.19 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,486 | 24 | 52.4% |
| Unspecified | $36,527 | 10 | 32.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,270 | 5 | 8.3% |
| Food and Beverage | $2,782 | 41 | 2.5% |
| Honoraria | $2,760 | 2 | 2.5% |
| Travel and Lodging | $1,577 | 9 | 1.4% |
| Education | $148.19 | 2 | 0.1% |
Payments by Type
General
$75,024
83 transactions
Research
$36,527
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $35,868 | 29 | $0 (2024) |
| Ichnos Sciences Inc. | $30,230 | 1 | $0 (2020) |
| Genentech USA, Inc. | $10,417 | 12 | $0 (2024) |
| PFIZER INC. | $6,065 | 4 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $5,915 | 12 | $0 (2021) |
| Lilly USA, LLC | $5,800 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $5,486 | 9 | $0 (2024) |
| Gilead Sciences, Inc. | $3,313 | 3 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,633 | 5 | $0 (2024) |
| Seagen Inc. | $2,570 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,269 | 19 | Genentech USA, Inc. ($7,580) |
| 2023 | $26,931 | 20 | AstraZeneca Pharmaceuticals LP ($21,941) |
| 2022 | $16,211 | 19 | Lilly USA, LLC ($5,800) |
| 2021 | $6,317 | 8 | AstraZeneca Pharmaceuticals LP ($2,767) |
| 2020 | $34,600 | 3 | Ichnos Sciences Inc. ($30,230) |
| 2019 | $2,869 | 7 | Genentech USA, Inc. ($2,724) |
| 2018 | $5,920 | 12 | Puma Biotechnology, Inc. ($5,864) |
| 2017 | $2,435 | 5 | Heron Therapeutics, Inc. ($2,342) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $80.24 | General |
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $113.52 | General |
| Category: ONC | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $2,193.75 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,640.00 | General |
| 09/16/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $44.70 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $378.44 | Research |
| Study: Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $97.93 | General |
| 06/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $48.31 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: Oncology | ||||||
| 05/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $67.49 | General |
| 04/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $2,868.75 | General |
| Category: Oncology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $505.01 | Research |
| Study: PIK3CA Testing and Treatment Patterns Among Metastatic Breast Cancer Patients in US Community Clinical Practice | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $278.71 | Research |
| Study: Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | ||||||
| 02/29/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,840.00 | General |
| 02/29/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $376.11 | General |
| 02/29/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $202.05 | General |
| 02/29/2024 | Genentech USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $102.53 | General |
| 02/29/2024 | Genentech USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $59.00 | General |
| 01/01/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $342.50 | General |
| Category: Oncology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,140.74 | Research |
| Study: Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | ||||||
| 12/15/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $4,452.50 | General |
| Category: Oncology | ||||||
| 12/14/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 12/07/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.19 | General |
| 12/06/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $127.54 | General |
| Category: Oncology | ||||||
| 12/05/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Other Study Related Fees | Ichnos Sciences Inc. | $30,230 | 1 |
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | F. Hoffmann-La Roche AG | $2,128 | 4 |
| PIK3CA Testing and Treatment Patterns Among Metastatic Breast Cancer Patients in US Community Clinical Practice | F. Hoffmann-La Roche AG | $505.01 | 1 |
| EMBER-2: A PHASE 1, OPEN-LABEL, PREOPERATIVE WINDOW STUDY EVALUATING THE BIOLOGICAL EFFECTS OF LY3484356 IN POST-MENOPAUSAL WOMEN WITH STAGE I-III ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER | Eli Lilly and Company | $263.25 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $200.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 31 | 74 | $31,350 | $5,725 |
| 2022 | 3 | 120 | 196 | $61,366 | $13,557 |
| 2021 | 5 | 204 | 339 | $102,915 | $28,103 |
| 2020 | 5 | 153 | 275 | $77,346 | $18,963 |
Total Patients
508
Total Services
884
Medicare Billing
$66,347
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 50 | $30,950 | $5,524 | 17.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 24 | $400.00 | $201.60 | 50.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 69 | 131 | $42,313 | $9,230 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 37 | 46 | $10,028 | $2,179 | 21.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 19 | $9,025 | $2,148 | 23.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 76 | 183 | $52,609 | $14,745 | 28.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 67 | 90 | $17,988 | $4,901 | 27.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $13,835 | $3,384 | 24.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 24 | $10,734 | $2,945 | 27.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 18 | 18 | $7,749 | $2,128 | 27.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 69 | 172 | $44,032 | $10,825 | 24.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 23 | 23 | $12,604 | $3,112 | 24.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 21 | $7,581 | $1,884 | 24.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 33 | 46 | $7,682 | $1,778 | 23.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 13 | 13 | $5,447 | $1,365 | 25.1% |
About Dr. Reva Basho, M.D
Dr. Reva Basho, M.D is a Hematology & Oncology healthcare provider based in West Hollywood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1508146721.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Reva Basho, M.D has received a total of $111,551 in payments from pharmaceutical and medical device companies, with $16,269 received in 2024. These payments were reported across 93 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($58,486).
As a Medicare-enrolled provider, Basho has provided services to 508 Medicare beneficiaries, totaling 884 services with total Medicare billing of $66,347. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location West Hollywood, CA
- Active Since 08/18/2011
- Last Updated 02/13/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1508146721
Products in Payments
- ICHNOS ISB 1302-103 (Drug) $30,230
- ENHERTU (Biological) $11,480
- Nerlynx (Drug) $5,864
- VERZENIO (Drug) $5,800
- KISQALI (Drug) $5,352
- LYNPARZA (Drug) $5,138
- Trodelvy (Drug) $3,313
- TALZENNA (Drug) $3,200
- IBRANCE (Drug) $2,865
- TUKYSA (Drug) $2,570
- CINVANTI (Drug) $2,342
- Kadcyla (Biological) $2,146
- Herceptin (Biological) $550.00
- Perjeta (Biological) $142.01
- NERLYNX (Drug) $50.16
- Enhertu (Drug) $48.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in West Hollywood
Dr. Richard Gould, Md, MD
Hematology & Oncology — Payments: $19,404
Hematology & Oncology $19,404
Dr. Justin Darrah, M.d, M.D
Hematology & Oncology — Payments: $5,989
Hematology & Oncology $5,989
Mouni Audeh, M.d, M.D
Hematology & Oncology — Payments: $133.67
Hematology & Oncology $133.67
Dr. Maria Delioukina, Md, MD
Hematology & Oncology — Payments: $17.98
Hematology & Oncology $17.98